| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.02. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 03.02.2026 | 1.044 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 03.02.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 03.02.2026ISIN NameAU0000234676 ENRG... ► Artikel lesen | |
| AQUAPORIN Aktie jetzt für 0€ handeln | |||||
| 02.02. | Aquaporin A/S - Removal from trading on Nasdaq Copenhagen | 734 | GlobeNewswire | Aquaporin A/S (the company) will be removed from trading on Nasdaq Copenhagen due to the company having been declared bankrupt.
Trading in the company's shares has been suspended since 30 January... ► Artikel lesen | |
| 02.02. | Aquaporin A/S: Bankruptcy order issued for Aquaporin A/S | 533 | GlobeNewswire (Europe) | Company announcement
No. 05/2026Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694Kongens Lyngby, Denmark, February 2, 2026 - The Bankruptcy Court... ► Artikel lesen | |
| 30.01. | XFRA 00B: AUSSETZUNG/SUSPENSION | 356 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILAQUAPORIN A/S DK... ► Artikel lesen | |
| 30.01. | Aquaporin A/S: Aquaporin announces withdrawal of its offering and resolves to initiate insolvency proceedings | 1.043 | PR Newswire | Company announcement No. 04/2026 Inside informationAquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694KONGENS LYNGBY, Denmark, Jan. 30, 2026... ► Artikel lesen | |
| 30.01. | Suspension of Trading in Aquaporin A/S at XCSE | 355 | GlobeNewswire | 2026-01-30T07:41:57Z
Suspension
At Trading Venue XCSE
Due to Technical Or
Administrative
Ongoing: True
Comments: We refer to company announcement No. 04
2026 disclosed by Aquaporin on January 30... ► Artikel lesen | |
| 26.01. | Aquaporin A/S: Aquaporin further postpones final results of rights issue due to current investor dialogues and uncertainty of completion | 383 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT... ► Artikel lesen | |
| 23.01. | Aquaporin A/S - Observation status | 379 | GlobeNewswire | Nasdaq Copenhagen has today given the below observation status:
ISIN NAME:
DK0061555109 AQUAPORIN
The company is given observation status because the company... ► Artikel lesen | |
| 23.01. | Aquaporin A/S: Aquaporin postpones final results of rights issue due to uncertainty of completion and its ability to remain a going concern | 360 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT... ► Artikel lesen | |
| 02.01. | Aquaporin A/S: Last day of trading in shares with pre-emptive rights in connection with rights issue | 647 | PR Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR... ► Artikel lesen | |
| 02.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.01.2026 | 752 | Xetra Newsboard | Das Instrument 00B DK0061555109 AQUAPORIN A/S DK 1 EQUITY wird cum Kapitalmassnahme gehandelt am 02.01.2026 und ex Kapitalmassnahme am 05.01.2026 The instrument 00B DK0061555109 AQUAPORIN A/S DK 1 EQUITY... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S - rights issue, admission to trading and official listing of subscription rights | 475 | GlobeNewswire | Subscription rights in Aquaporin A/S will be admitted to trading and official listing on Nasdaq Copenhagen as of 5 January 2026. As of the same date, ISIN DK0061555109 (AQP) will be traded excl.... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S: Aquaporin initiates rights issue | 637 | PR Newswire | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION WHERE IT WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE OR... ► Artikel lesen | |
| 19.12.25 | Aquaporin A/S: Aquaporin updates on strategic review and sets mid-and long-term financial targets | 952 | PR Newswire | Company announcementNo. 21/2025Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY... ► Artikel lesen | |
| 01.12.25 | Business transacted at the extraordinary general meeting of Aquaporin A/S | 552 | PR Newswire | Company announcementNo. 20/2025Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany reg. no.: DK28315694KONGENS LYNGBY, Denmark, Dec. 1, 2025 /PRNewswire/ -- Aquaporin A/S... ► Artikel lesen | |
| 01.12.25 | Aquaporin A/S: Business transacted at the extraordinary general meeting of Aquaporin A/S | 348 | GlobeNewswire (Europe) | Company announcement
No. 20/2025
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company reg. no.: DK28315694
Kongens Lyngby, Denmark, December 1, 2025 - Aquaporin A/S ("Aquaporin"... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,200 | 0,00 % | QIAGEN N.V.: QIAGEN-Aktionäre stimmen der Berufung von Jonathan M. Pratt in die Geschäftsführung mit überwältigender Mehrheit zu | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute bekannt gegeben, dass die Aktionärinnen und Aktionäre auf einer Außerordentlichen Hauptversammlung der Berufung von Jonathan M. Pratt... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 10,500 | 0,00 % | Summit Therapeutics (SMMT) Is Losing Wall Street's Confidence | ||
| DISC MEDICINE | 77,98 | 0,00 % | Disc Medicine auf der Jefferies Global Healthcare Conference: Bitopertin auf Erholungskurs | ||
| TANGO THERAPEUTICS | 21,890 | 0,00 % | Tango Therapeutics (NDQ:TNGX): Its Pancreatic Cancer Data Was Extraordinary And Shares Have Tripled, But Are Investors Getting Ahead Of Themselves? | ||
| CG ONCOLOGY | 80,01 | +0,01 % | Truist hebt Kursziel für CG Oncology nach Studiendaten an | ||
| ERASCA | 13,780 | +0,15 % | Erasca, Bristol Myers Squibb Partner To Study Combination Therapy In Pancreatic Cancer | NEW YORK CITY (dpa-AFX) - Erasca, Inc. (ERAS) announced a clinical trial collaboration with Bristol Myers Squibb (BMY) to evaluate ERAS-0015, Erasca's investigational pan-RAS molecular glue... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,020 | +0,05 % | Beam Therapeutics auf UBS-Konferenz: Forcierte Plattformstrategie und BLA-Antrag für Sichelzelltherapie in Sicht | ||
| PRAXIS PRECISION MEDICINES | 304,85 | -0,11 % | Guggenheim hebt Kursziel für Praxis Precision Medicines auf 1.050 $ an - Kaufempfehlung bestätigt | ||
| HARMONY BIOSCIENCES | 33,110 | 0,00 % | H.C. Wainwright bekräftigt Kaufempfehlung für Harmony Bio mit Kursziel von 55 Dollar | ||
| INHIBRX BIOSCIENCES | 69,06 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx Announces Updated Clinical Data for Ozekibart (INBRX-109) in Ewing Sarcoma | - Ozekibart combination in relapsed/refractory Ewing sarcoma achieves 62.7% ORR;- 86.3% DCR, with durable responses observed in heavily pretreated patients SAN DIEGO, Nov. 17, 2026 /PRNewswire/ -- Inhibrx... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 23,400 | 0,00 % | Rapport Therapeutics präsentiert Pipeline-Fortschritte und Phase-III-Fahrplan auf der Jefferies Global Healthcare Conference | ||
| RECURSION PHARMACEUTICALS | 2,820 | -0,18 % | Recursion auf der Jefferies Global Healthcare Conference: KI-Pipeline gewinnt an klinischer Dynamik | ||
| ARRIVENT BIOPHARMA | 10,900 | 0,00 % | Guggenheim senkt Kursziel für ArriVent BioPharma auf $28 | ||
| COGENT BIOSCIENCES | 27,815 | +0,02 % | Cogent Biosciences auf Jefferies-Konferenz: Markteinführungspläne hängen an Bezuclastinib | ||
| DYNE THERAPEUTICS | 15,880 | +0,06 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen |